Alteration of macrophage infiltrates in the tumor immune microenvironment following Janus kinase 1 (JAK) inhibition: analysis from a prospective clinical trial in Leiomyosarcoma
7 affiliations
- 1Sarcoma Center, Dana-Farber Cancer Institute, Boston, MA, USA
- 2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
- 3Medical Oncology, City of Hope Cancer Center, Duarte, CA, USA
- 4Medicine, Brigham and Women’s Hospital, Boston, MA, USA
- 5Medical Oncology, Northwestern University, Chicago, IL, USA
- 6Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA
- 7Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
Abstract
JAK1 signaling supports a suppressive tumor-associated macrophage (TAM) state and may also promote tumor-intrinsic oncogenic signaling. Leiomyosarcoma (LMS) is a soft tissue sarcoma (STS) subtype known to have abundant TAM infiltration, which is often polarized to an immunosuppressive M2 phenotype and contributes to immune evasion. We hypothesized that using a JAK1 inhibitor could alter TAM phenotypes in the LMS tumor microenvironment (TME), helping patients and potentially enabling future combination studies. Here, we present results from a pilot study of itacitinib, a JAK1 inhibitor, for LMS. We analyzed patients in the LMS cohort of a pilot study of the selective JAK1 inhibitor itacitinib (started at 300 mg daily in 28-day cycles) (NCT03670069). Serial tumor biopsies and peripheral blood samples were collected for correlative analysis. Despite the heavily pretreated LMS population, PFS rate at 3 and 6 months for LMS was 75% (95% CI: 50%–100%) and 25% (95% CI: 5%–100%), respectively, and the median OS was 101 weeks (range: 70–256). Six of eight patients with LMS achieved stable disease. Serial biopsies demonstrated a decrease in M2 TAM but without a corresponding inflammatory response and with a decrease of inflammatory infiltrates, suggesting that JAK1 inhibition may have direct anti-tumor effects in this subtype and that the impacts of the TAM reduction may be related to their tumor supportive and angiogenic functions, rather than immune inhibitory functions. These data support further investigation of JAK1 inhibition in LMS as part of rational immunotherapeutic combinations.
Related
- Macrophage- or neutrophil-expressed UPP1 drives tumor growth and immune suppression in the tumor microenvironment
- Integrated in silico and 3D in vitro model of macrophage migration in response to physical and chemical factors in the tumor microenvironment
- The Efferocytosis-Driven Macrophage Polarization: A Concerto in the Tumor Immunosuppressive Microenvironment.
- Beyond density: mapping the functional landscapes of macrophage-T lymphocyte niches in the tumor microenvironment
- Macrophage lipid efflux regulates the tumour microenvironment in early‐stage lung adenocarcinoma
BibTeX
@article{wagner2026alteration,
title = {{Alteration of macrophage infiltrates in the tumor immune microenvironment following Janus kinase 1 (JAK) inhibition: analysis from a prospective clinical trial in Leiomyosarcoma}},
author = {Michael J. Wagner and Lee D. Cranmer and Elizabeth T. Loggers and Roxanne Moore and Hannah R. Abrams and Shannon Hill and Anirudh Goyal and Munther Baroudi and Niall Morin and Juliana Chi Kei Ng and Valeria Valentina Vizcaino and Himaly Shinglot and Daphne P. Edgren and Nourhane Al Akoum and Weiqing Jing and Rusul Al-Marayaty and Borislav Alexiev and Ruohui Chen and Minggang Lin and Rylee Johnson and Kimberly S. Smythe and Lauri D. Aicher and Cecilia C. S. Yeung and Seth M. Pollack},
journal = {Oncoimmunology},
year = {2026},
month = nov,
doi = {10.1080/2162402x.2026.2755668},
url = {https://doi.org/10.1080/2162402x.2026.2755668},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Alteration of macrophage infiltrates in the tumor immune microenvironment following Janus kinase 1 (JAK) inhibition: analysis from a prospective clinical trial in Leiomyosarcoma
AU - Michael J. Wagner
AU - Lee D. Cranmer
AU - Elizabeth T. Loggers
AU - Roxanne Moore
AU - Hannah R. Abrams
AU - Shannon Hill
AU - Anirudh Goyal
AU - Munther Baroudi
AU - Niall Morin
AU - Juliana Chi Kei Ng
AU - Valeria Valentina Vizcaino
AU - Himaly Shinglot
AU - Daphne P. Edgren
AU - Nourhane Al Akoum
AU - Weiqing Jing
AU - Rusul Al-Marayaty
AU - Borislav Alexiev
AU - Ruohui Chen
AU - Minggang Lin
AU - Rylee Johnson
AU - Kimberly S. Smythe
AU - Lauri D. Aicher
AU - Cecilia C. S. Yeung
AU - Seth M. Pollack
PY - 2026
DA - 2026/11/06
JO - Oncoimmunology
DO - 10.1080/2162402x.2026.2755668
UR - https://doi.org/10.1080/2162402x.2026.2755668
AB - JAK1 signaling supports a suppressive tumor-associated macrophage (TAM) state and may also promote tumor-intrinsic oncogenic signaling. Leiomyosarcoma (LMS) is a soft tissue sarcoma (STS) subtype known to have abundant TAM infiltration, which is often polarized to an immunosuppressive M2 phenotype and contributes to immune evasion. We hypothesized that using a JAK1 inhibitor could alter TAM phenotypes in the LMS tumor microenvironment (TME), helping patients and potentially enabling future combination studies. Here, we present results from a pilot study of itacitinib, a JAK1 inhibitor, for LMS. We analyzed patients in the LMS cohort of a pilot study of the selective JAK1 inhibitor itacitinib (started at 300 mg daily in 28-day cycles) (NCT03670069). Serial tumor biopsies and peripheral blood samples were collected for correlative analysis. Despite the heavily pretreated LMS population, PFS rate at 3 and 6 months for LMS was 75% (95% CI: 50%–100%) and 25% (95% CI: 5%–100%), respectively, and the median OS was 101 weeks (range: 70–256). Six of eight patients with LMS achieved stable disease. Serial biopsies demonstrated a decrease in M2 TAM but without a corresponding inflammatory response and with a decrease of inflammatory infiltrates, suggesting that JAK1 inhibition may have direct anti-tumor effects in this subtype and that the impacts of the TAM reduction may be related to their tumor supportive and angiogenic functions, rather than immune inhibitory functions. These data support further investigation of JAK1 inhibition in LMS as part of rational immunotherapeutic combinations.
SN - 2162-4011
SN - 2162-402X
ER -